Once-daily versus twice-daily vigabatrin: Is there a difference? The results of a double-blind pilot study

Epilepsia

Volumn 40, Issue 3, 1999, Pages 311-315

  Zahner, B ^a   Stefan, H ^a   Blankenhorn, V ^b   Kramer G ^c   Richens, A ^d   Thumler R ^e   Mumford, J P ^f  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Epilepsie Zentrum   (Germany)

^c SWISS EPILEPSY CENTER   (Switzerland)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e Rheinhessen Fachklinik   (Germany)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMINOTRANSFERASE; VIGABATRIN;

ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; EPILEPSY; FEMALE; GABAERGIC SYSTEM; HUMAN; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032965098     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00710.x     Document Type: Article

References (13)

1. Elliott KA, van Gelder NM. Occlusion and metabolism of GABA by brain tissue. J Neurochem 1958;3:28-40.
2. Bey P. Mechanism-based enzyme inhibitors as an approach to drug design. In: Palfreyman MG, McCann PP, Lovenberg W, Temple JR Jr, Sjoedsma A, eds. Enzymes as targets for drug design. San Diego: Academic Press, 1989:59-83.
3. Ben-Menachem E, Persson LI, Schechter PJ, et al. Effects of single doses of vigabatrin on CSF concentrations of GABA. homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epilepsy Res 1988;2:96-101.
4. Ben-Menachem E, Persson LI, Schlechter PJ, et al. The effect of different vigabatrin treatment regiments on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989;27 (suppl 1):79-85.
5. Petroff OAC, Rothman DL, Behar DL, Collins TL, Mattson RH. The acute effects of vigabatrin on brain GABA concentration in patients with intractable epilepsy. Neurology 1996;46(suppl): A277-9.
6. Mattson RH, Petroff OAC, Rothman DL, Behar KL, Collins TL. Oral vigabatrin raises brain GABA within two hours. Epilepsia 1996;37:203.
7. Trostle J. Doctor's orders and patient's self-interests: two views of medication usage? In: Schmidt D, Leppik IE, eds. Compliance in epilepsy. Amsterdam: Elsevier, 1988:57-70.
8. Jacobs J, Goldstein AG, Kelly ME, Bloom BS. NSAID dosing schedule and compliance. Drug Intell Clin Pharm 1988;22:717-28.
9. Aldenkamp AP, Alpherts WCJ et al. Controlled release of carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 1987;28:507-14.
10. MacPhee GJA. Butler H, Brodie MJ. Intradose and arcadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism. Epilepsia 1987;28:213-7.
11. Cramer JA, Mattson RH, Prevey M, Ouellelte VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7.
12. Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995;36:1111-7.
13. Leroy RF, Felts CA, Eltermann RD, North RR, Naarden AL. A comparison of adverse events of daily versus twice daily vigabatrin (Sabril) dosing. Epilepsia 1995;36:54.